BioSpace News Archive

Qualigen Therapeutics, Inc. today announces its financial results for the second quarter ended June 30, 2022, and provides an update on its therapeutic pipeline and other corporate developments.

Medison Pharma announced today the expansion of its partnership with Albireo to a multi-regional agreement to commercialize Odevixibat in Canada and Israel.

Tris Pharma, Inc. announced today that DYANAVEL® XR (amphetamine) extended-release tablets, for oral use, CII are now available in pharmacies.

Virax Biolabs (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today announced that Chairman of the Board and Chief Executive Officer, James Foster will ring the Nasdaq Stock Market closing bell on Thursday, August 18, 2022.

Palatin Technologies, Inc. today announced the results of a planned interim analysis of the Phase 3 pivotal study of PL9643 (MELODY-1) in patients with dry eye disease (DED).

Today, Inc. revealed that BioCare, Inc. , a leading specialty pharmaceutical distribution partner that provides distribution, specialty pharmacy and logistics services, was named on its annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America.

Miravo Healthcare ™ Announces Appointment of Anthony Snow to its Board of Directors.

BioImpact Capital, an affiliate of MPM Capital, announced that Orna Therapeutics, a portfolio company it created, incubated, and funded, has agreed to a landmark collaboration with one of the world’s leading biopharmaceutical companies.

Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Chief Executive Officer Dr. Megan Baldwin will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference, taking place virtually on August 17, 2022.

QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of bone cancer and related diseases, today announces financial results for the second quarter ended June 30, 2022, as filed with the SEC on August 15, 2022 in the Company’s Form 10-Q, and provides a corporate update.